MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing...
- Mechanism
- Curator reviewed
MB07803 is a selective inhibitor of fructose-1, 6-bisphosphatase (FBPase), a regulatory enzyme in the pathway responsible for the production of glucose in the liver, known as the gluconeogenesis pathway. By specifically inhibiting this pathway, liver glucose production should be reduced and blood sugar levels decreased in patients with diabetes, independent of insulin levels and body weight.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
- Formula / weight
- C24H37N4O7PS · 556.61 g/mol (avg)
- Code names
- MB-07803
Resolves to
CTKZZUXRWBCFEI-UHFFFAOYSA-NSMILESCCOC(=O)C(C)(C)NP(=O)(NC(C)(C)C(=O)OCC)C1=CC=C(O1)C1=C(SC(N)=N1)C(=O)C(C)(C)CWhat you can answer from here — as of January 29, 2025
Which drugs share a target with MB-07803, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account